Глоссарий
Понятные технические термины
Определения всех терминов, автоматически связанных по всей платформе. Буквы переходят к разделу.
A
- Agonistagonistic · full agonist · partial agonistМеханизм действия
- Substance that activates a receptor, thereby mimicking or augmenting the action of the endogenous ligand.
- Angiogenesisangiogenic · neovascularisation · neovascularizationМеханизм действия
- Formation of new blood vessels from existing ones. A key process in wound healing, tissue growth and tumour biology.
B
- BioavailabilitybioavailableФармакология
- Proportion of an administered substance that reaches systemic circulation unchanged. Particularly dependent on route of administration and digestive stability for peptide substances.
- Blindingdouble-blind · blindedКонечная точка исследования
- Procedure in which participants and/or researchers do not know who receives treatment or placebo. Reduces expectation bias.
C
- Cochrane reviewCochraneКонечная точка исследования
- Systematic review by the Cochrane Collaboration using standardised methodology for literature search, study appraisal and optional meta-analysis. Considered the methodological gold standard for evidence synthesis.
- Compoundingcompounding pharmacyРегуляторика
- Individual preparation of a medicinal product in a pharmacy, distinct from an industrially approved product. Subject to its own regulatory rules.
D
- DiarrhoeadiarrheaКонечная точка исследования
- Increased stool frequency (>3 per day) with reduced consistency. Most frequent gastrointestinal adverse event of all GLP-1 receptor agonists, usually mild and dose-dependent.
E
- Endpointprimary endpoint · secondary endpointКонечная точка исследования
- Pre-specified outcome measure of a study. The primary endpoint determines statistical power; secondary endpoints are exploratory.
G
- GHRHGrowth-hormone-releasing hormoneМеханизм действия
- Hypothalamic peptide that stimulates growth-hormone secretion from the pituitary gland.
- GLP-1Glucagon-like peptide-1Механизм действия
- Incretin hormone released in the gut after food intake. Glucose-dependently stimulates insulin secretion, suppresses glucagon and delays gastric emptying.
- Glucoseblood sugar · dextroseМеханизм действия
- Monosaccharide (C₆H₁₂O₆), the central energy carrier of the body. Taken up into cells via insulin and released from the liver under glucagon action. Blood glucose concentration is the key parameter for diabetes diagnostics and management.
H
- Half-lifet½ · elimination half-lifeФармакология
- Time during which the concentration of an active substance in the body falls to half. A modelling assumption — real-world pharmacokinetics can be more complex.
- HbA1cglycated haemoglobinКонечная точка исследования
- Glycated haemoglobin — marker of average blood-glucose levels over the past 8–12 weeks. Key endpoint in diabetes studies.
- Hepatitisliver inflammationКонечная точка исследования
- Inflammation of the liver due to viruses (A-E), alcohol, medication, autoimmunity or other causes. Chronic hepatitis C is an indication adjunctively studied with thymalin in Russian trials.
- Hyperglycaemiahyperglycemia · high blood sugarКонечная точка исследования
- State of too high blood glucose, by definition fasting ≥126 mg/dL or ≥7.0 mmol/L. Chronic hyperglycaemia is the defining feature of diabetes mellitus.
- Hypoglycaemiahypoglycemia · low blood sugarКонечная точка исследования
- State of too low blood glucose (<70 mg/dL or <3.9 mmol/L). Clinically relevant as an adverse event of many antidiabetic therapies — GLP-1 analogs rarely trigger it due to their glucose-dependent mechanism.
- HypothalamushypothalamicМеханизм действия
- Region in the diencephalon controlling the pituitary via releasing and inhibiting hormones (GHRH, TRH, GnRH, somatostatin, dopamine, CRH). Also a central regulatory centre for appetite, temperature and sleep-wake rhythm.
I
- IGF-1Insulin-like growth factor 1Механизм действия
- Growth factor whose level is regulated by growth hormone. Often used as a surrogate marker for GH activity.
- In vitrocell cultureКонечная точка исследования
- "In glass" — experiment outside a living organism, usually in cell culture. Findings do not automatically transfer to humans.
- In vivoКонечная точка исследования
- "In the living" — experiment in a living organism, typically animal or human.
L
- Lyophilisatelyophilized · lyophilised · freeze-driedТехнический
- Freeze-drying product in which water has been removed by sublimation under vacuum. A stable storage form for many peptides.
O
- Off-labeloff-label useРегуляторика
- Use of an approved medicinal product outside its approved indication, dose or patient population.
- Osteoporosisbone lossКонечная точка исследования
- Condition of reduced bone density and disturbed micro-architecture leading to increased fracture risk. Key therapy lines: bisphosphonates, denosumab, teriparatide, romosozumab; historically also salmon calcitonin.
P
- PancreaspancreaticМеханизм действия
- Organ with exocrine (digestive enzymes) and endocrine function (insulin from β-cells, glucagon from α-cells, somatostatin from δ-cells). Central role in glucose homeostasis.
- Pancreatitispancreas inflammationКонечная точка исследования
- Inflammation of the pancreas, acute or chronic. Acute pancreatitis is a potential adverse event of all GLP-1 receptor agonists and is listed as a warning on the label — causality remains debated.
- PharmacodynamicsPD · pharmacodynamicФармакология
- What a substance does to the body: mechanism of action, effect size, dose-response.
- PharmacokineticsPK · pharmacokineticФармакология
- What the body does to a substance: absorption, distribution, metabolism, excretion.
- Pituitary glandpituitaryМеханизм действия
- Hormone gland at the base of the brain with anterior lobe (adenohypophysis: GH, TSH, ACTH, FSH, LH, prolactin) and posterior lobe (neurohypophysis: oxytocin, vasopressin). Controls superordinate endocrine axes.
- Placebo effectplaceboКонечная точка исследования
- Improvement in subjective or measurable endpoints due to expectation of effect, independent of the actual substance.
- PreclinicalКонечная точка исследования
- Studies before clinical use in humans — usually in vitro or in animal models.
- Prostate cancerprostate carcinomaКонечная точка исследования
- Most common malignant tumour in men. Hormone-sensitive subtypes respond to androgen deprivation therapy — including GnRH agonists (leuprolide, goserelin, triptorelin) or GnRH antagonists (degarelix, relugolix).
R
- RCTRandomised controlled trial · Randomized controlled trialКонечная точка исследования
- Gold standard of clinical research. Participants are randomly allocated to treatment and control groups; ideally blinded.
- ReceptorreceptorsМеханизм действия
- Protein to which a signalling molecule (e.g. hormone or peptide) binds, triggering a cellular response.
- ReconstitutionreconstituteТехнический
- Dissolving a dry (lyophilised) substance in a liquid to obtain a ready-to-use solution.
S
- Signalling pathwaysignaling pathway · signaling pathwaysМеханизм действия
- Cascade of molecular events through which a signal is transduced from the cell surface to a cellular response.
W
- WADAWorld Anti-Doping AgencyРегуляторика
- International organisation coordinating anti-doping rules in sport and publishing the annual Prohibited List.